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Menstrually related migraine (MRM) is defined as occur-
ring from days -2 to +3 of menstruation in at least 2 out of
3 menstrual cycles, and additionally at other times of the
menstrual cycle. MRM is generally longer lasting, more
severe, and more difficult to treat compared to non-MRM
attacks. MAP0004 is an investigational orally inhaled
dihydroergotamine (DHE) for the acute treatment of
migraine. In a large Phase 3 study, MAP0004 was effective
and well tolerated in treating an acute migraine attack
compared to placebo. This post-hoc analysis compares the
efficacy of MAP0004 in treating MRM versus non-MRM,
including an analysis of recurrence rates using 4 different,
previously published recurrence rate definitions. The
efficacy of MAP0004, as measured by pain relief at 2 hours,
pain free at 2 hours, sustained pain relief at 2-24 and
2-48 hours, and sustained pain free at 2-24 and 2-48 hours
values, was not significantly different between subjects with
MRM and non-MRM. Furthermore, the MRM recurrence
rates after pain relief were not statistically higher than that
of non-MRM treated with MAP0004. There were no
significant differences in the frequency of adverse events for
MRM vs. non-MRM subjects, and no drug-related serious
adverse events were reported. In the study, MAP0004 was
effective and well-tolerated for both MRM and non-MRM.
Author details
1Swedish Neuroscience Institute, Swedish Headache Center, Seattle, WA,
USA. 2MAP Pharmaceuticals, USA.
Published: 21 February 2013
References
1. Headache Classification Subcommittee of the International Headache
Society: The international classification of headache disorders.
Cephalalgia 2004, 24(suppl 1).
2. Granella F, et al: Characteristics of menstrual and nonmenstrual attacks in
women with menstrually related migraine referred to headache centres.
Cephalalgia 2004, 24(9):707-716.
3. Sacco S, et al: Migraine in women: the role of hormones and their
impact on vascular diseases. J Headache Pain 2012, 13(3):177-89,
Epub2012Feb26.
doi:10.1186/1129-2377-14-S1-P143
Cite this article as: Aurora et al.: Analysis of subjects with menstrually
related migraine vs. Non-menstrually related migraine treated with
MAP0004. The Journal of Headache and Pain 2013 14(Suppl 1):P143.
Submit your manuscript to a 
journal and benefi t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the fi eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com1Swedish Neuroscience Institute, Swedish Headache Center, Seattle, WA, USA
2MAP Pharmaceuticals, USA
Full list of author information is available at the end of the article
Aurora et al. The Journal of Headache and Pain 2013, 14(Suppl 1):P143
http://www.thejournalofheadacheandpain.com/content/14/S1/P143
© 2013 Aurora et al; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.
